Barchart on MSN2d
2 ‘Strong Buy’ Stocks Under $10 Set to Surge as Much as 331%
Generally, a “Strong Buy” rating on Wall Street indicates that analysts believe the stock will appreciate and outperform the ...
The Pharma Letter2d
The week in pharma: action, reaction and insight – week to February 21
Last week’s significant news was dominated by licensing deals and mergers and acquisitions. US biotech giant Biogen entered ...
Pharm Exec5d
Biogen, Stoke Therapeutics Ink Deal to Develop Zorevunersen for Dravet Syndrome
Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...
PMLiVE6d
Biogen gains rights to Stoke’s Dravet syndrome candidate in deal worth $550m
Biogen and Stoke Therapeutics have announced a partnership aimed at advancing a disease-modifying treatment for Dravet ...
precisionmedicineonline6d
Biogen Inks Deal to Commercialize Stoke Therapeutics' Dravet Syndrome ASO; Stoke Retains US Rights
Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.